Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash-to-Debt 1.43
SGYP's Cash-to-Debt is ranked lower than
57% of the 790 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. SGYP: 1.43 )
Ranked among companies with meaningful Cash-to-Debt only.
SGYP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.13  Med: No Debt Max: No Debt
Current: 1.43
Piotroski F-Score: 3
Altman Z-Score: -3.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROA % -139.45
SGYP's ROA % is ranked lower than
97% of the 798 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. SGYP: -139.45 )
Ranked among companies with meaningful ROA % only.
SGYP' s ROA % Range Over the Past 10 Years
Min: -6858.53  Med: -154.23 Max: -69.97
Current: -139.45
-6858.53
-69.97
ROC (Joel Greenblatt) % -21539.48
SGYP's ROC (Joel Greenblatt) % is ranked lower than
98% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.01 vs. SGYP: -21539.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SGYP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -423053.33  Med: -74545.45 Max: -666.67
Current: -21539.48
-423053.33
-666.67
3-Year EBITDA Growth Rate 13.90
SGYP's 3-Year EBITDA Growth Rate is ranked higher than
58% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.50 vs. SGYP: 13.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SGYP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 29.2 Max: 131.7
Current: 13.9
0
131.7
3-Year EPS without NRI Growth Rate 20.10
SGYP's 3-Year EPS without NRI Growth Rate is ranked higher than
68% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.30 vs. SGYP: 20.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SGYP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 29.1 Max: 122.4
Current: 20.1
0
122.4
GuruFocus has detected 2 Warning Signs with Synergy Pharmaceuticals Inc $SGYP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SGYP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

SGYP Guru Trades in Q1 2016

Paul Tudor Jones 48,161 sh (+118.18%)
John Paulson 11,090,000 sh (+23.22%)
Jim Simons Sold Out
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
» More
Q2 2016

SGYP Guru Trades in Q2 2016

John Paulson 27,756,668 sh (+150.29%)
Paul Tudor Jones 34,385 sh (-28.60%)
» More
Q3 2016

SGYP Guru Trades in Q3 2016

John Paulson 24,228,655 sh (-12.71%)
Paul Tudor Jones 18,144 sh (-47.23%)
» More
Q4 2016

SGYP Guru Trades in Q4 2016

Paul Tudor Jones 18,376 sh (+1.28%)
John Paulson 24,088,655 sh (-0.58%)
» More
» Details

Insider Trades

Latest Guru Trades with SGYP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:DEPO, OTCPK:EVTCY, OTCPK:TWMJF, NAS:IPXL, OTCPK:NPPNY, NAS:MNTA, NYSE:LCI, NAS:EGRX, NAS:HRTX, NAS:SUPN, NAS:AMPH, NAS:SCMP, NAS:SCLN, OTCPK:ACBFF, NAS:ACET, NAS:LBIO, OTCPK:ARSUF, NAS:PCRX, OTCPK:OWCP, NAS:RIGL » details
Traded in other countries:S90.Germany,
Synergy Pharmaceuticals Inc is a biopharmaceutical company. It engages in the development of drugs to treat gastrointestinal, or GI, disorders and diseases.

Synergy Pharmaceuticals Inc was incorporated under the laws of the State of Florida on November 15, 2005 as Pawfect Foods, Inc. The Company is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal, or GI, disorders and diseases. Its product candidate is plecanatide, a guanylate cyclase C, or GC-C, receptor agonist, to treat GI disorders, primarily chronic idiopathic constipation, or CIC, and constipation-predominant- irritable bowel syndrome, or IBS-C. CIC and IBS-C are functional gastrointestinal disorders that afflict millions of sufferers worldwide. CIC is primarily characterized by constipation symptoms but a majority of these patients report experiencing straining, bloating and abdominal discomfort as among their most bothersome symptoms. IBS-C is characterized by frequent and recurring abdominal pain and/or discomfort associated with chronic constipation. The Company's main competitors include major pharmaceutical and biotechnology companies focusing on GI such as Ironwood Pharmaceuticals, Inc., Forest Laboratories, Inc., and Takeda. The Company is subject to various environmental, health and safety regulations including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials.

Top Ranked Articles about Synergy Pharmaceuticals Inc

John Paulson Trims Synergy Company is among many drug manufacturers in portfolio
John Paulson (Trades, Portfolio) of Paulson & Co. reduced his holdings in Synergy Pharmaceuticals (NASDAQ:SGYP) by 12.5% on Sept. 19. Read more...

Ratios

vs
industry
vs
history
PB Ratio 81.95
SGYP's PB Ratio is ranked lower than
99% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. SGYP: 81.95 )
Ranked among companies with meaningful PB Ratio only.
SGYP' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 106.29
Current: 81.95
0
106.29
Current Ratio 4.71
SGYP's Current Ratio is ranked higher than
75% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. SGYP: 4.71 )
Ranked among companies with meaningful Current Ratio only.
SGYP' s Current Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2.83 Max: 11.88
Current: 4.71
0.04
11.88
Quick Ratio 4.71
SGYP's Quick Ratio is ranked higher than
78% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. SGYP: 4.71 )
Ranked among companies with meaningful Quick Ratio only.
SGYP' s Quick Ratio Range Over the Past 10 Years
Min: 0.04  Med: 2.83 Max: 11.88
Current: 4.71
0.04
11.88

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -19.50
SGYP's 3-Year Average Share Buyback Ratio is ranked lower than
82% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. SGYP: -19.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SGYP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -248.4  Med: -21.2 Max: -14.6
Current: -19.5
-248.4
-14.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 109.80
SGYP's Price-to-Net-Cash is ranked lower than
96% of the 250 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.84 vs. SGYP: 109.80 )
Ranked among companies with meaningful Price-to-Net-Cash only.
SGYP' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.63  Med: 22.61 Max: 582
Current: 109.8
4.63
582
Price-to-Net-Current-Asset-Value 91.50
SGYP's Price-to-Net-Current-Asset-Value is ranked lower than
97% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SGYP: 91.50 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
SGYP' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.48  Med: 16.22 Max: 301.5
Current: 91.5
4.48
301.5
Price-to-Tangible-Book 78.43
SGYP's Price-to-Tangible-Book is ranked lower than
99% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. SGYP: 78.43 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SGYP' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.45  Med: 16.76 Max: 597.69
Current: 78.43
4.45
597.69
Earnings Yield (Greenblatt) % -13.62
SGYP's Earnings Yield (Greenblatt) % is ranked lower than
86% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. SGYP: -13.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SGYP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -36.2  Med: 0 Max: 0
Current: -13.62
-36.2
0

More Statistics

EPS (TTM) $ -1.22
Beta1.63
Short Percentage of Float21.56%
52-Week Range $2.50 - 7.15
Shares Outstanding (Mil)179.95

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 41 200 226
EPS ($) -1.07 -0.45 0.17 0.26
EPS without NRI ($) -1.07 -0.45 0.17 0.26
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for SGYP

Headlines

Articles On GuruFocus.com
John Paulson Trims Synergy Sep 23 2016 
Paul Tudor Jones' Highest Performing Stocks Jul 13 2015 
Monday Pre-Market Insights: Pluristem Therapeutics, Juno Therapeutics, OraSure Technologies, Synergy May 18 2015 

More From Other Websites
Did 50 Salespeople Leave Valeant? Wells Fargo Investigates Feb 23 2017
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Feb 15 2017
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 08 2017
Synergy Pharmaceuticals to Present at Leerink Partners 6th Annual Global Healthcare Conference Feb 08 2017
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Feb 07 2017
Pivotal Phase 3 Data Results for TRULANCE™ (plecanatide) in the Treatment of Chronic Idiopathic... Feb 07 2017
Price For Synergy Pharmaceuticals Inc (SGYP) Public Offering Announced Feb 03 2017
SYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Feb 02 2017
How to Trade Hot Stocks Apple, Seadrill, Advanced Micro Devices Feb 01 2017
Fail, win and then fail some more to become a winning trader Feb 01 2017
The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals... Feb 01 2017
Premarket Biotech Movers: Synergy, Arrowhead, BioCryst Feb 01 2017
Synergy Pharma stock sinks 12.5% after announcement of common stock offering Feb 01 2017
Synergy Pharmaceuticals Announces Pricing of Public Offering of Common Stock Feb 01 2017
Synergy Pharmaceuticals Announces Proposed Public Offering of Common Stock Jan 31 2017
4 FDA Decisions to Watch Out for in Feb 2017 Jan 31 2017
FDA Approves Trulance From Synergy Pharmaceuticals Inc (SGYP) To Battle With Allergan PLC (AGN)... Jan 25 2017
UPDATE 1-Synergy wins U.S. approval for constipation drug (Jan 19) Jan 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)